Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE)

BACKGROUND: Treatment for ovarian cancer includes platinum-based chemotherapy, but many women become resistant to chemotherapy, becoming platinum-resistant. Standard of care for these women is weekly paclitaxel chemotherapy, but cancers can often become paclitaxel resistant. TAK228, an investigation...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Rosa, Consuelo Nóhpal, Krell, Jonathan, Day, Emily, Clarke, Aaron, Reddi, Meena, Webber, Lee, Fiorentino, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728702/
https://www.ncbi.nlm.nih.gov/pubmed/34986897
http://dx.doi.org/10.1186/s13063-021-05669-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728702/
https://www.ncbi.nlm.nih.gov/pubmed/34986897
http://dx.doi.org/10.1186/s13063-021-05669-9

Ejemplares similares